ViiV Healthcare submits regulatory application to EMA for investigational Cabotegravir to be used in combination with Rilpivirine for HIV

This article was originally published here

The application also includes data for cabotegravir oral tablets, intended for use as oral lead-in therapy prior to the commencement of injectable therapy. Deborah Waterhouse, CEO of ViiV

The post ViiV Healthcare submits regulatory application to EMA for investigational Cabotegravir to be used in combination with Rilpivirine for HIV appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply